
GeneriCo develops and markets niche generic pharmaceuticals, focusing on complex formulations overlooked by larger firms.
GeneriCo was founded with the mission to develop and market niche generic pharmaceuticals that are often neglected by mid-sized and large pharmaceutical companies. The company focuses on complex formulations that require advanced drug delivery technologies, making their pipeline unattractive to larger competitors and too challenging for smaller firms. GeneriCo aims to address gaps in the market by providing high-quality, technically challenging generic drugs.
Notable affiliated people and investors include industry experts with extensive experience in pharmaceutical development and investment. GeneriCo has achieved significant milestones in bringing complex generic formulations to market, thereby improving access to essential medications. Their impact lies in filling a critical void in the pharmaceutical industry by offering specialized generics that larger companies overlook, thereby enhancing patient care and treatment options.

Solaris Pharma
solaris-pharma.com

Saptalis Pharmaceuticals

Genzum Life Sciences
genzum.com

Generian Pharmaceuticals
generian.com

Genteric

US Specialty Formulations

Vitruvias Therapeutics
vitruvias.com

G2B Pharma

Bionpharma
bionpharma.com

Pyros Pharmaceuticals
pyrospharma.com

Concours Pharmaceuticals

Meitheal Pharmaceuticals
meithealpharma.com

R K Pharma
rkpharmainc.com

Continuity Pharma

Leading Pharma
leadingpharma.com
Companies similar to Generico include Solaris Pharma, Saptalis Pharmaceuticals, Genzum Life Sciences and Generian Pharmaceuticals.
Generico was founded in 2013.
Generico's headquarters is located in St. Louis, MO, US.
Generico's most recent funding round was for $1.5M (USD) in July 2015.
As of Jul 28, 2015, Generico has raised a total of $1.9M (USD).